Research Analysts’ Weekly Ratings Changes for Becton, Dickinson and (BDX)

A number of firms have modified their ratings and price targets on shares of Becton, Dickinson and (NYSE: BDX) recently:

  • 8/10/2017 – Becton, Dickinson and had its “equal weight” rating reaffirmed by analysts at Barclays PLC. They now have a $210.00 price target on the stock, up previously from $205.00.
  • 8/9/2017 – Becton, Dickinson and had its “buy” rating reaffirmed by analysts at Stifel Nicolaus.
  • 8/7/2017 – Becton, Dickinson and was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Becton, Dickinson and Company, popularly known as BD, saw a mixed third quarter, wherein adjusted earnings beat the Zacks Consensus Estimate, while revenues missed the same. A solid guidance for fiscal 2017 instills our confidence in the stock. The company is steadily progressing with its planned acquisition of medical technology player, C. R. Bard. The $24-billion transaction is slated to be completed in the fourth quarter. Post completion, BD expects growth in adjusted earnings starting fiscal 2019. We view the acquisition as a strategic fit which will generate benefits from complementary businesses and geographical expansion. BD's cost-control initiatives are also noteworthy. On the flipside, unfavorable sales performance from the BD Medical segment is a concern. Massive growth in the segment was negated by sluggishness in the Medication Management Solutions and Pharmaceutical Systems units in the U.S.”
  • 8/6/2017 – Becton, Dickinson and was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 7/31/2017 – Becton, Dickinson and was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 7/21/2017 – Becton, Dickinson and had its “buy” rating reaffirmed by analysts at Bank of America Corporation. They now have a $225.00 price target on the stock, up previously from $200.00.
  • 7/17/2017 – Becton, Dickinson and was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $225.00 price target on the stock. According to Zacks, “Becton, Dickinson and Company, popularly known as BD, is steadily moving towards its announced acquisition of medical technology player, C. R. Bard. The $24 billion transaction is slated to be completed in the fourth quarter. Post completion of the acquisition, BD expects growth in adjusted earnings starting fiscal 2019. We believe the acquisition to be a strategic fit and would generate benefits from complementary businesses and geographical expansion. Becton's cost-control initiatives are also noteworthy. On the flipside, unfavorable sales performance from the BD Medical segment is a concern. Also, adverse foreign exchange is likely to pose major headwinds for the rest of the fiscal. Furthermore, the company had an unfavorable run on the bourse over the last three months, trading significantly below the broader industry.”
  • 7/11/2017 – Becton, Dickinson and was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 7/10/2017 – Becton, Dickinson and had its “outperform” rating reaffirmed by analysts at Cowen and Company. They now have a $230.00 price target on the stock, up previously from $200.00.
  • 6/30/2017 – Becton, Dickinson and was upgraded by analysts at Raymond James Financial, Inc. from an “outperform” rating to a “strong-buy” rating. They now have a $180.00 price target on the stock, down previously from $210.00.

Becton, Dickinson and Company (NYSE:BDX) opened at 198.22 on Friday. The firm’s 50 day moving average is $198.75 and its 200-day moving average is $187.49. Becton, Dickinson and Company has a 12 month low of $161.29 and a 12 month high of $206.63. The firm has a market cap of $45.11 billion, a price-to-earnings ratio of 57.41 and a beta of 1.05.

Becton, Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, beating the consensus estimate of $2.44 by $0.02. The company had revenue of $3.04 billion during the quarter, compared to analysts’ expectations of $3.06 billion. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. Becton, Dickinson and’s revenue for the quarter was down 5.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.35 earnings per share. On average, equities analysts forecast that Becton, Dickinson and Company will post $9.45 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 8th will be paid a dividend of $0.73 per share. The ex-dividend date is Thursday, September 7th. This represents a $2.92 annualized dividend and a yield of 1.47%. Becton, Dickinson and’s dividend payout ratio is currently 83.43%.

In related news, insider Thomas E. Polen, Jr. sold 5,971 shares of the business’s stock in a transaction that occurred on Wednesday, August 9th. The shares were sold at an average price of $197.41, for a total transaction of $1,178,735.11. Following the completion of the transaction, the insider now owns 12,861 shares of the company’s stock, valued at $2,538,890.01. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP Jeffrey S. Sherman sold 28,765 shares of the business’s stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $185.98, for a total transaction of $5,349,714.70. Following the transaction, the vice president now directly owns 70,821 shares of the company’s stock, valued at approximately $13,171,289.58. The disclosure for this sale can be found here. 1.40% of the stock is currently owned by insiders.

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.